Spots Global Cancer Trial Database for utomilumab
Every month we try and update this database with for utomilumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | NCT03414658 | Breast Cancer | Vinorelbine Trastuzumab Avelumab Utomilumab | 18 Years - | Dana-Farber Cancer Institute | |
| RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA | NCT03636503 | Follicular Lymp... | Rituximab Utomilumab Avelumab PF04518600 | 18 Years - | Dana-Farber Cancer Institute | |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | NCT03440567 | Recurrent Diffu... Recurrent Mantl... Refractory Diff... Refractory Mant... Transformed Fol... | Autologous Hema... Avelumab Carboplatin Etoposide Phosp... Ibrutinib Ifosfamide Laboratory Biom... Rituximab Utomilumab | 18 Years - | City of Hope Medical Center | |
| RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA | NCT03636503 | Follicular Lymp... | Rituximab Utomilumab Avelumab PF04518600 | 18 Years - | Dana-Farber Cancer Institute | |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | NCT03440567 | Recurrent Diffu... Recurrent Mantl... Refractory Diff... Refractory Mant... Transformed Fol... | Autologous Hema... Avelumab Carboplatin Etoposide Phosp... Ibrutinib Ifosfamide Laboratory Biom... Rituximab Utomilumab | 18 Years - | City of Hope Medical Center | |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | NCT03217747 | Advanced Malign... Castration-Resi... Malignant Solid... Metastatic Mali... Metastatic Pros... Prostate Carcin... Refractory Mali... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Avelumab Ivuxolimab Radiation Thera... Utomilumab | 18 Years - | M.D. Anderson Cancer Center | |
| T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | NCT03318900 | COL6A3 Positive HLA-A*0201 Posi... PRAME Positive Recurrent Ovari... | Aldesleukin CD8-Positive T-... Cyclophosphamid... Leukapheresis Utomilumab | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | NCT03971409 | Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Invasive Breast... Recurrent Breas... Triple-Negative... Unresectable Br... | Anti-OX40 Antib... Avelumab Binimetinib Utomilumab Liposomal Doxor... Sacituzumab Gov... | 18 Years - | University of California, San Francisco | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | NCT03258008 | Malignant Neopl... Malignant Neopl... Oropharyngeal C... | Utomilumab ISA101b | 18 Years - | M.D. Anderson Cancer Center | |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | NCT03414658 | Breast Cancer | Vinorelbine Trastuzumab Avelumab Utomilumab | 18 Years - | Dana-Farber Cancer Institute | |
| Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | NCT02951156 | Diffuse Large B... | Avelumab Utomilumab Rituximab Azacitidine Bendamustine Gemcitabine Oxaliplatin | 18 Years - | Pfizer | |
| Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | NCT03290937 | Metastatic Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... | Cetuximab Irinotecan Hydr... Pharmacodynamic... Utomilumab | 16 Years - | M.D. Anderson Cancer Center | |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | NCT03364348 | HER2 Positive B... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Utomilumab Trastuzumab Ado-Trastuzumab... | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
